Anbalcabtagene Autoleucel

Preferred Label : Anbalcabtagene Autoleucel;

NCIt synonyms : Autologous Anti-CD19 CAR T Cells CRC01; Autologous Anti-CD19 CAR-T Cells CRC01;

NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anbalcabtagene autoleucel targets and binds to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.;

UNII : 9JHE6G6VCM;

Molecule name : CRC-01; CRC 01;

NCI Metathesaurus CUI : CL1662952;

Details

Origin ID

C180584;

UMLS CUI

C5783438;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients